Chapter 38 — Key Takeaways

Standing caveat, because this chapter needs it more than any other: everything below describes regulatory structures, mostly those of the United States. They differ by jurisdiction and they change. Nothing here is legal advice, and nothing here tells you what you may lawfully buy, import, or possess. If you have a real question, verify current rules for your own jurisdiction with someone qualified to read them.

The one sentence

Regulatory status tells you what has been submitted and judged. Evidence tells you what is known. They correlate; they are not the same thing.

What an approval is (§38.1)

• An approval is a regulator's judgment that, for a specified indication and population, the evidence submitted shows benefits outweigh risks, plus an approved label describing that use.
• It is indication-specific — not a certificate about a molecule. "Approved" without an indication is an incomplete sentence.
• It is based on the evidence submitted — so an unapproved use may be unstudied rather than rejected.
• It is jurisdiction-specific, and agencies applying similar principles routinely reach different conclusions.
• It does not mean the drug works for everyone, that long-term effects are known, that it beats the alternatives, or that the judgment is permanent.

The forty-amino-acid line (§38.2)

• United States, as of this writing: an alpha-amino-acid polymer with a specific, defined sequence of more than 40 amino acids is a biological product (BLA); 40 or fewer is a drug (NDA).
• The consequence is not cosmetic. It decides the follow-on competition pathway: drugs get generics via abbreviated applications resting on bioequivalence; biologics get biosimilars, a far more demanding and expensive route with a separate interchangeability determination.
• Insulin is 51 amino acids in two chains. Historically approved as a drug; under a statutory transition effective March 2020 it was deemed a biological product, which opened the biosimilar pathway for it.
• Semaglutide's backbone is 31 residues — the drug side. Tirzepatide at 39 sits two residues from the line.
• The line counts residues, not daltons. Modified peptides can carry large non-amino-acid mass without moving toward it.
• How a molecule is classified shapes what happens after exclusivity ends — which connects the line to Chapter 12's access argument and §36.9's patent discussion.

The pathway (§38.3)

• Preclinical → IND (permission to test, not an approval) → Phase 1 (safety, tolerability, PK; small, often healthy volunteers) → Phase 2 (dose-finding, preliminary efficacy) → Phase 3 (adequate and well-controlled efficacy trials) → review → Phase 4 / post-marketing surveillance.
• Most compounds entering the pipeline do not finish it, and attrition concentrates where human efficacy is first tested (Chapter 10).
• Accelerated pathways permit approval on a surrogate endpoint with confirmatory trials required. The surrogate-endpoint problem (Chapter 16) is therefore a designed feature of regulation, not a hypothetical criticism of it — confirmation is deferred, not waived.

The five meanings of "not FDA approved" (§38.4)

• "Not FDA approved" is a statement about a regulatory file, not about a molecule.
• BPC-157 is case (1). Chapter 17's ❌ rests on the empty human literature, not on the regulatory status.

Off-label (§38.5)

• In the United States and many other jurisdictions, a licensed prescriber may lawfully prescribe an approved drug for an unapproved indication; manufacturers may not promote off-label use.
• The asymmetry is deliberate: it preserves clinical freedom while keeping the evidentiary burden on the party that profits from the claim.
• Off-label is not a synonym for unsupported. Some off-label uses rest on substantial published evidence nobody had reason to submit; others rest on almost nothing.
• The label tells you what was submitted and approved. It does not tell you what is known.

Compounding (§38.6)

• 503A — traditional pharmacy compounding on patient-specific prescriptions, exempt from certain requirements including premarket approval.
• 503B outsourcing facilities — larger scale, may compound without patient-specific prescriptions, subject to GMP requirements and federal inspection.
• Neither involves premarket review of safety or efficacy, and compounded drugs are not FDA-approved products. That row is identical across both categories and is the one people miss.
• Shortage mechanism: listing permits compounding of what would otherwise be an essentially-a-copy product in defined circumstances; declaring the shortage resolved narrows that permission and compounders must wind down. This is the GLP-1 story of the mid-2020s, and the details and timing were contested, including in litigation.
• A compounded version of a drug is not the approved drug — different salt forms, concentrations, devices, and additives are all live possibilities (Chapter 19).

Research chemicals and supplements (§38.7)

• "For research use only — not for human consumption" is a liability posture, not a regulatory category. The disclaimer transfers risk without changing what the product is.
• DSHEA (1994) created a United States supplement category with no premarket approval requirement — but a substance must qualify as a dietary ingredient to be sold in it, and regulators have taken the position that certain peptides, BPC-157 among them, do not.
• Compounds have also been placed on lists identifying significant safety risks for compounding use.
• "Sold as a supplement" is not a regulatory endorsement, and for several compounds in this book it is not even a lawful classification.

Doping (§38.8)

• WADA publishes a Prohibited List, updated annually.
• S2 — Peptide Hormones, Growth Factors, Related Substances and Mimetics: growth hormone, secretagogues and GHRH analogs, IGF-1 and analogs, erythropoiesis-affecting agents (Chapters 14, 15, 16).
• S0 — Non-Approved Substances: any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use is prohibited at all times.
• BPC-157 was added under S0, effective from the 2022 List.
• S0 makes "it isn't on the banned list" wrong by construction. It is a rule about a property, not a list of names — an unapproved compound is prohibited precisely because it is unapproved.
• The sanction does not depend on whether it works. Chapter 17's ❌ and the S0 prohibition are simultaneously true and entirely independent.
• These rules bind athletes in tested sport. Anyone subject to them should check the current List.

The international patchwork (§38.9)

• FDA, EMA, MHRA, PMDA, TGA and national authorities apply broadly similar principles and reach different conclusions — because of genuinely different evidence standards, different filings by sponsors, different medical practice and unmet need, and different timing.
• Import and personal-possession rules differ enormously and this book does not advise on them.
• "Approved in [country]" is a fact worth knowing and a poor substitute for looking at the evidence that approval rested on — which may have been strong, weak, or considerably lighter than a reader assumes.

Status is not evidence, in both directions (§38.10)

Error 1 — approval as proof. Approval does not mean the drug works for other uses, works for everyone, has known long-term effects, or beats the alternatives. Nesiritide was approved in the United States in 2001 on a symptom endpoint and a large outcome trial published in 2011 found no benefit on the endpoints that mattered most. Accelerated approvals rest on surrogates by design. Approval is strong evidence about a narrow claim — and both words matter.

Error 2 — non-approval as proof of absence. Used dishonestly in both directions: by sellers calling it suppression, by skeptics calling it refutation. For most gray-market peptides the accurate statement is a chain: no one submitted an application; no one submitted because no one funded the trials; no one funded the trials because there is no patentable commercial position in a well-known short sequence. That is a structural fact about drug economics, not about biology — and it predicts that good and bad compounds alike go unstudied, which is exactly why an empty file carries no information.

The conclusion: treat a regulatory fact as a pointer, not a verdict. Chapter 5's method is the one you apply — not the label.

Dossier — Field 10 completed

• Field 10 is status, and it took five chapters to fill because "what is the status of this compound?" is five different questions: what the sales channel claims about itself (Ch. 6), access and cost and who is selling (Ch. 12), what is actually in the vial (Ch. 19), what a certificate of analysis can and cannot establish (Ch. 34), and status with regulators and sporting authorities (Ch. 38).
• Record: approved anywhere and for what indication; which of the five meanings applies; prohibited in tested sport, under which category and from which List year; how it is actually being sold.
• Record it in a column entirely separate from the evidence rating, and never let one adjust the other. A compound can be approved somewhere and thinly evidenced; a compound can be unapproved everywhere and simply untested.